Development of effective anti-influenza drugs: congeners and conjugates–a review

JJ Shie, JM Fang - Journal of Biomedical Science, 2019 - Springer
Influenza is a long-standing health problem. For treatment of seasonal flu and possible
pandemic infections, there is a need to develop new anti-influenza drugs that have good …

Influenza neuraminidase: a druggable target for natural products

U Grienke, M Schmidtke, S von Grafenstein… - Natural product …, 2012 - pubs.rsc.org
Covering: 2000 to 2011 The imminent threat of influenza pandemics and repeatedly
reported emergence of new drug-resistant influenza virus strains demonstrate the urgent …

Mesoscale all-atom influenza virus simulations suggest new substrate binding mechanism

JD Durrant, SE Kochanek, L Casalino… - ACS central …, 2020 - ACS Publications
Influenza virus circulates in human, avian, and swine hosts, causing seasonal epidemic and
occasional pandemic outbreaks. Influenza neuraminidase, a viral surface glycoprotein, has …

[PDF][PDF] Prediction of protein structure and interaction by GALAXY protein modeling programs

WH Shin, GR Lee, L Heo, H Lee, C Seok - Bio Design, 2014 - scholar.archive.org
The last century has witnessed remarkable advances in computational chemistry and
computational biology, and computational approaches are increasingly and more widely …

Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition

CJ Vavricka, Q Li, Y Wu, J Qi, M Wang, Y Liu… - PLoS …, 2011 - journals.plos.org
The 2009 H1N1 influenza pandemic (pH1N1) led to record sales of neuraminidase (NA)
inhibitors, which has contributed significantly to the recent increase in oseltamivir-resistant …

Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase

LS Cheng, RE Amaro, D Xu, WW Li… - Journal of medicinal …, 2008 - ACS Publications
Avian influenza virus subtype H5N1 is a potential pandemic threat with human-adapted
strains resistant to antiviral drugs. Although virtual screening (VS) against a crystal or …

Identification of chebulinic acid and chebulagic acid as novel influenza viral neuraminidase inhibitors

P Li, R Du, Y Wang, X Hou, L Wang, X Zhao… - Frontiers in …, 2020 - frontiersin.org
The influenza A virus (IAV) causes seasonal epidemics and occasional but devastating
pandemics, which are of a major public health concern. Although several antiviral drugs are …

Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus

Q Li, X Sun, Z Li, Y Liu, CJ Vavricka… - Proceedings of the …, 2012 - National Acad Sciences
The recent discovery of the unique genome of influenza virus H17N10 in bats raises
considerable doubt about the origin and evolution of influenza A viruses. It also identifies a …

[HTML][HTML] New small-molecule drug design strategies for fighting resistant influenza A

Z Shen, K Lou, W Wang - Acta Pharmaceutica Sinica B, 2015 - Elsevier
Influenza A virus is the major cause of seasonal or pandemic flu worldwide. Two main
treatment strategies–vaccination and small molecule anti-influenza drugs are currently …

Mechanism of 150-cavity formation in influenza neuraminidase

RE Amaro, RV Swift, L Votapka, WW Li… - Nature …, 2011 - nature.com
The recently discovered 150-cavity in the active site of group-1 influenza A neuraminidase
(NA) proteins provides a target for rational structure-based drug development to counter the …